Borneol Depresses P-Glycoprotein Function by a NF-κB Signaling Mediated Mechanism in a Blood Brain Barrier in Vitro Model

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2015 Nov 24

PMID 26593909

Citations 27

Authors

Xiang Fan

Lijuan Chai

Han Zhang

YueFei Wang

Boli Zhang

Xiumei Gao

Affiliations

Soon will be listed here.

Abstract

P-glycoprotein (P-gp) on brain microvascular endothelial cells (BMECs) that form the blood brain barrier (BBB), influences transportation of substances between blood and brain. The objective of this study was to characterize the effects of borneol on P-gp efflux function on BBB and explore the potential mechanisms. We established an in vitro BBB model comprised of rat BMECs and astrocytes to measure the effects of borneol on the known P-gp substrates transport across BBB, and examined the function and expression of P-gp in BMECs and the signaling pathways regulating P-gp expression. Borneol increased intracellular accumulation of Rhodamine 123, enhanced verapamil and digoxin across the BBB in vitro model, and depressed mdr1a mRNA and P-gp expression. Borneol could activate nuclear factor-κB (NF-κB) and inhibition of NF-κB with MG132 (carbobenzoxy-Leu-Leu-leucinal) and SN50 (an inhibitory peptide) obscuring the P-gp decreases induced by borneol. These data suggested that borneol depresses P-gp function in BMECs by a NF-κB signaling medicated mechanism in a BBB in vitro model.

Citing Articles

Much More than Nutrients: The Protective Effects of Nutraceuticals on the Blood-Brain Barrier in Diseases.

Kocsis A, Kucsapszky N, Santa-Maria A, Hunyadi A, Deli M, Walter F Nutrients. 2025; 17(5).

PMID: 40077636 PMC: 11901837. DOI: 10.3390/nu17050766.

Comprehensive evaluation of Dragon's Blood in combination with borneol in ameliorating ischemic/reperfusion brain injury using RNA sequencing, metabolomics, and 16S rRNA sequencing.

Ren J, Zhang X, Zhou L, Cao W, Zhang L, Chen X Front Pharmacol. 2024; 15:1372449.

PMID: 38783945 PMC: 11112420. DOI: 10.3389/fphar.2024.1372449.

Research progress on the regulation and mechanism of borneol on the blood-brain barrier in pathological states: a narrative review focused on ischemic stroke and cerebral glioma.

Tan X, Zhang K, Shi W, Tang Z Transl Cancer Res. 2023; 12(11):3198-3209.

PMID: 38130309 PMC: 10731338. DOI: 10.21037/tcr-23-1487.

Exploring the potential to enhance drug distribution in the brain subregion via intranasal delivery of nanoemulsion in combination with borneol as a guider.

Shen X, Cui Z, Wei Y, Huo Y, Yu D, Zhang X Asian J Pharm Sci. 2023; 18(6):100778.

PMID: 38089837 PMC: 10711392. DOI: 10.1016/j.ajps.2023.100778.

Anticonvulsant effects of isopimpinellin and its interactions with classic antiseizure medications and borneol in the mouse tonic-clonic seizure model: an isobolographic transformation.

Luszczki J, Bojar H, Jankiewicz K, Florek-Luszczki M, Chmielewski J, Skalicka-Wozniak K Pharmacol Rep. 2023; 75(6):1533-1543.

PMID: 37821793 PMC: 10661746. DOI: 10.1007/s43440-023-00532-x.

References

Ogretmen B, Safa A . Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region. Biochemistry. 1999; 38(7):2189-99. DOI: 10.1021/bi982236+. View

Letrent S, Pollack G, Brouwer K, Brouwer K . Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos. 1999; 27(7):827-34. View

Thevenod F, Friedmann J, Katsen A, Hauser I . Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem. 2000; 275(3):1887-96. DOI: 10.1074/jbc.275.3.1887. View

Schinkel . P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev. 2000; 36(2-3):179-194. DOI: 10.1016/s0169-409x(98)00085-4. View

Sukhai M, Piquette-Miller M . Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci. 2000; 3(2):268-80. View

Miller D, Nobmann S, Gutmann H, Toeroek M, Drewe J, Fricker G . Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol. 2000; 58(6):1357-67. DOI: 10.1124/mol.58.6.1357. View

Karssen A, Meijer O, van der Sandt I, Lucassen P, de Lange E, De Boer A . Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology. 2001; 142(6):2686-94. DOI: 10.1210/endo.142.6.8213. View

Ros J, Schuetz J, Geuken M, Streetz K, Moshage H, Kuipers F . Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling. Hepatology. 2001; 33(6):1425-31. DOI: 10.1053/jhep.2001.24667. View

van der Sandt I, Smolders R, Nabulsi L, Zuideveld K, De Boer A, Breimer D . Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier. Eur J Pharm Sci. 2001; 14(1):81-6. DOI: 10.1016/s0928-0987(01)00150-6. View

10.

Litman T, Druley T, Stein W, Bates S . From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci. 2001; 58(7):931-59. PMC: 11337370. DOI: 10.1007/PL00000912. View

11.

Potschka H, Loscher W . In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia. 2001; 42(10):1231-40. DOI: 10.1046/j.1528-1157.2001.01901.x. View

12.

Felix R, Barrand M . P-glycoprotein expression in rat brain endothelial cells: evidence for regulation by transient oxidative stress. J Neurochem. 2002; 80(1):64-72. DOI: 10.1046/j.0022-3042.2001.00660.x. View

13.

Kuo M, Liu Z, Wei Y, Lin-Lee Y, Tatebe S, Mills G . Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene. 2002; 21(13):1945-54. DOI: 10.1038/sj.onc.1205117. View

14.

Lundquist S, Renftel M, Brillault J, Fenart L, Cecchelli R, Dehouck M . Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharm Res. 2002; 19(7):976-81. DOI: 10.1023/a:1016462205267. View

15.

Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N . NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003; 22(1):90-7. DOI: 10.1038/sj.onc.1206056. View

16.

Lundquist S, Renftel M . The use of in vitro cell culture models for mechanistic studies and as permeability screens for the blood-brain barrier in the pharmaceutical industry--background and current status in the drug discovery process. Vascul Pharmacol. 2003; 38(6):355-64. DOI: 10.1016/s1537-1891(02)00203-3. View

17.

Abbott N, Hughes C, Revest P, Greenwood J . Development and characterisation of a rat brain capillary endothelial culture: towards an in vitro blood-brain barrier. J Cell Sci. 1992; 103 ( Pt 1):23-37. DOI: 10.1242/jcs.103.1.23. View

18.

Nwaozuzu O, Sellers L, Barrand M . Signalling pathways influencing basal and H(2)O(2)-induced P-glycoprotein expression in endothelial cells derived from the blood-brain barrier. J Neurochem. 2003; 87(4):1043-51. DOI: 10.1046/j.1471-4159.2003.02061.x. View

19.

Dagenais C, Graff C, Pollack G . Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol. 2003; 67(2):269-76. DOI: 10.1016/j.bcp.2003.08.027. View

20.

Chen Y, Wang N . [Effect of borneol on the intercellular tight junction and pinocytosis vesicles in vitro blood-brain barrier model]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004; 24(7):632-4. View